Inventor · disambiguated record
Daniel C. Adelman
Also filed as: ADELMAN DANIEL · ADELMAN DANIEL C
8 granted patents·15 pending applications·27 citations·filing 2005–2020
83Inventor score
Files withSUNESIS PHARMACEUTICALS INC9ADELMAN DANIEL C6NESTLE SA3AIMMUNE THERAPEUTICS INC2ALVINE PHARMACEUTICALS INC1
Top patents by PatentIndex Score
23 records- 0191US8124773B21,8-naphthyridine compounds for the treatment of cancerADELMAN DANIEL C·Filed 2007·Granted Feb 28, 2012·10 cites·13 claims
- 0290US7989468B2Methods of using SNS-595SUNESIS PHARMACEUTICALS INC·Filed 2005·Granted Aug 2, 2011·13 cites·43 claims
- 0383US8580814B2Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancerADELMAN DANIEL C·Filed 2006·Granted Nov 12, 2013·3 cites·24 claims
- 0476US8765954B21,8-naphthyridine compounds for the treatment of cancerADELMAN DANIEL C·Filed 2012·Granted Jul 1, 2014·1 cites·8 claims
- 0570US2015150858A1Compounds and compositions for treatment of cancerSUNESIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 0664US2014378505A1Sns-595 and methods of using the sameSUNESIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 0763US2022415464A1Methods and systems for managing distribution and treatment of a food allergy oral immunotherapy drugNESTLE SA·Filed 2020·Application pending·0 cites
- 0862US9757363B2SNS-595 and methods of using the sameSUNESIS PHARMACEUTICALS INC·Filed 2016·Granted Sep 12, 2017·0 cites·17 claims
- 0962US2021151155A1Methods and systems for managing distribution and treatment of a food allergy oral immunotherapy drugAIMMUNE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1061US9676774B2Compounds and compositions for treatment of cancerSUNESIS PHARMACEUTICALS INC·Filed 2016·Granted Jun 13, 2017·0 cites·6 claims
- 1157US2006025437A1SNS-595 and methods of using the sameADELMAN DANIEL C·Filed 2005·Application pending·0 cites
- 1255US12433945B2Peanut oral immunotherapy with maintenance doseNESTLE SA·Filed 2019·Granted Oct 7, 2025·0 cites·14 claims
- 1354US2015190380A1Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disordersSUNESIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1453US2014205680A1Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancerSUNESIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1553US2008063642A1Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disordersADELMAN DANIEL C·Filed 2007·Application pending·0 cites
- 1651US2018098975A1Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancerSUNESIS PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 1747US2022046948A1Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergyAIMMUNE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1846US2017119745A1Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disordersSUNESIS PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1946US2011293745A1Aurora kinase inhibitorsHOCH UTE·Filed 2009·Application pending·0 cites
- 2045US2014248251A1Methods and Pharmaceutical Compositions for Treating Celiac Disease and Gluten IntoleranceADELMAN DANIEL C·Filed 2012·Application pending·0 cites
- 2145US2018104317A1Methods and pharmaceutical compositions for treating celiac disease and gluten intoleranceIMMUNOGENICS LLC·Filed 2017·Application pending·0 cites
- 2244US12226448B2Peanut oral immunotherapy dosing schedule for missed dosesNESTLE SA·Filed 2019·Granted Feb 18, 2025·0 cites·20 claims
- 2339US2015223747A1Patient reported outcome instrumentALVINE PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Daniel C. Adelman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →